Details

NameSymbolSector
PARMAX PHARMA LIMITEDPARMAXPharmaceuticals
Open
133.75
High
133.75
Low
133.75
Close
133.75
Volume
2018
Exchange
bse
Time
07-Sep-2026

Outlook

Score:  

3.25

Rating:  

FAIR

Candlestick Pattern

Candle pattern of Parmax Pharma is  
Doji
Estimated Stoploss of Parmax Pharma is ₹  
133.75
Parmax Pharma has a  
Bearishℹ
 pattern. 
Formation of  
Doji
 candle pattern indicates the trend direction of Parmax Pharma is  
Unpredictableℹ
. 

Trend

Parmax Pharma is in  
Uptrendℹ
. 
Price of Parmax Pharma is  
Upℹ
 by  

38.34

%. 
Target
Buy @ 

102.7

Sell @ 

133.75

Current @ 

133.75

Volume

The trade volumes of Parmax Pharma have become  
Deficientℹ
Though the volume trend for Parmax Pharma appears  
Bullishℹ
 the participants seem to be  
Weak Buyersℹ
The trade volume of Parmax Pharma is  

Down

 by  

84.2

% 

Valuation

The current market price of Parmax Pharma is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 18cr and total assets worth ₹ 18cr, the balance sheet of Parmax Pharma is:  
Balancedℹ
. 
Cashflow
Parmax Pharma has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

0% in operatingℹ
0% in investingℹ
100% i.e. ₹ 1cr earned in financingℹ
0% in otherℹ
Parmax Pharma has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2024)

0% in operatingℹ
50% i.e. ₹ 1cr spent in investingℹ
50% i.e. ₹ 1cr earned in financingℹ
0% in otherℹ
Income
The income of Parmax Pharma is  

₹ 2cr

 and  

Loss

 is :  

₹ 2cr

(*Sep 2025)

Parmax Pharma Losses increased by:  

200

% and Income is Up by:  

100

% 

(*Sep 2025)

The income of Parmax Pharma is  

₹ 1cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Parmax Pharma Losses decreased by:  

100

% and Income is Down by:  

75

% 

(*Jun 2025)

The income of Parmax Pharma is  

₹ 4cr

 and  

Loss

 is :  

₹ 1cr

(*Mar 2025)

Parmax Pharma Losses increased by:  

100

% and Income is Down by:  

33.33

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.